Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Laith J Abu-Raddad;
Hiam Chemaitelly
;
Houssein H Ayoub;
Hadi M Yassine;
Fatiha M Benslimane;
Hebah A Al Khatib;
Patrick Tang;
Mohammad R Hasan;
Peter Coyle;
Sawsan AlMukdad;
+14 more...
Zaina Al Kanaani;
Einas Al Kuwari;
Andrew Jeremijenko;
Anvar Hassan Kaleeckal;
Ali Nizar Latif;
Riyazuddin Mohammad Shaik;
Hanan F Abdul Rahim;
Gheyath K Nasrallah;
Mohamed Ghaith Al Kuwari;
Adeel A Butt;
Hamad Eid Al Romaihi;
Mohamed H Al-Thani;
Abdullatif Al Khal;
Roberto Bertollini;
(2021)
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75 (1).
e1188-e1191.
ISSN 1058-4838
DOI: 10.1093/cid/ciab909
Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.
Item Type | Article |
---|---|
Elements ID | 166806 |
Share this file
Downloads
ORCID: https://orcid.org/0000-0002-8756-6968